Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04MGW
|
|||
| Former ID |
DNCL003448
|
|||
| Drug Name |
BI-836858
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 2 | [1], [2] | |
| Acute myeloid leukaemia [ICD-11: 2A60] | Phase 1/2 | [1], [2] | ||
| Company |
Boehringer Ingelheim Pharmaceuticals
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myeloid cell surface antigen CD33 (CD33) | Target Info | . | [3] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014 Jul;28(4):143-53. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.